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Abstract
Objective Bronchiectasis is an important component of cystic
fibrosis (CF) lung disease but little is known about its devel-
opment. We aimed to study the development of bronchiectasis
and identify determinants for rapid progression of bronchiec-
tasis on chest CT.
Methods Forty-three patients with CF with at least four con-
secutive biennial volumetric CTs were included. Areas with
bronchiectasis on the most recent CTwere marked as regions
of interest (ROIs). These ROIs were generated on all preced-
ing CTs using deformable image registration. Observers indi-
cated whether: bronchiectasis, mucus plugging, airway wall
thickening, atelectasis/consolidation or normal airways were
present in the ROIs.
Results We identified 362 ROIs on the most recent CT. In 187
(51.7 %) ROIs bronchiectasis was present on all preceding
CTs, while 175 ROIs showed development of bronchiectasis.
In 139/175 (79.4 %) no pre-stages of bronchiectasis were
identified. In 36/175 (20.6 %) bronchiectatic airways the fol-
lowing pre-stages were identified: mucus plugging (17.7 %),
airway wall thickening (1.7 %) or atelectasis/consolidation
(1.1 %). Pancreatic insufficiency was more prevalent in the
rapid progressors compared to the slow progressors (p=0.05).
Conclusion Most bronchiectatic airways developed within
2 years without visible pre-stages, underlining the treacherous
nature of CF lung disease. Mucus plugging was the most
frequent pre-stage.
Key Points
• Development of bronchiectasis in cystic fibrosis lung dis-
ease on CT.
• Most bronchiectatic airways developed within 2 years with-
out pre-stages.
• The most frequently identified pre-stage was mucus
plugging.
• This study underlines the treacherous nature of CF lung
disease.
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FEV1 Forced expiratory volume in 1 s
FVC Forced vital capacity
ROI Region of interest
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Introduction
An important component of cystic fibrosis (CF) lung disease
is bronchiectasis [1]. Bronchiectasis is a permanent and irre-
versible abnormal dilatation of the bronchial lumen and is
most reliably detected by chest computed tomography (CT)
[2–5].
Bronchiectasis has been observed on chest CT in infants
with CF as young as 10 weeks of age [6–11]. At 3–5 years of
age, 50–70 % of children with CF already have bronchiecta-
sis, which contributes importantly to the morbidity and mor-
tality in CF [6, 8, 12]. To prevent the development of bronchi-
ectasis it is of great clinical importance to identify early pre-
stages on CT with the aim of preventing further progression.
Mucus plugging, airway wall thickening and atelectasis or
consolidation have been observed to develop early in life in
many patients and these changes could potentially be pre-
stages for the development of bronchiectasis [1]. Studies
showed that once bronchiectatic airways are present, they
progress in severity [1, 6, 10, 13, 14]. However, it remains
unclear how bronchiectatic airways evolve and why progres-
sion is more rapid in some patients [15].
Therefore, this study aims to identify pre-stages of bron-
chiectasis in CF on chest CT and to determine which patients
are at risk for a rapid progression of bronchiectasis.
Methods
Study population
This retrospective study used longitudinally collected clin-
ical data from the routine annual evaluation of CF patients
under treatment in the Erasmus MC-CF Center (Rotterdam,
The Netherlands) from January 2005–May 2013. We in-
cluded 43 clinically stable CF patients who had at least
four consecutive volumetric inspiratory CTs to guarantee
a minimum follow-up period of 6 years. A routine chest
CT is performed biennially as part of the annual evaluation
programme. During this study period the annual evaluation
programme was changed to structure the follow-up sched-
ule for routine chest CTs, so that every child with CF has a
CT at the same age (6, 8, 10, 12, 14, 16, 18 years).
Patients who had a lung transplant in the study period were
excluded. Furthermore, patients with a pulmonary exacerba-
tion or pulmonary complications (e.g. pneumothorax or
haemoptysis) at the time of CT scanning were excluded. A
pulmonary exacerbation was defined as receiving intravenous
antibiotics for respiratory symptoms.
We denoted the most recent available volumetric CT made
during annual evaluation as CTbaseline. CTminus2,4,6,8 are denot-
ed as respectively the CTs made 2, 4, 6 or 8 years prior to
CTbaseline.
This study was approved by the Institutional Review Board
of the Erasmus MC-CF Center (MEC-2013-593).
CTacquisition and spirometry
CTs were performed on different CT scanners using different
low-dose protocols. Most CTs (77.8 %) were predominantly
executed on the Emotion 6 (Siemens Emotion 6, Siemens
Healthcare, Germany). Since 2010 the remainder of the scans
were made on a new CT scanner (SOMATOM Definition
Flash, Siemens Healthcare, Germany). More details about
the CT protocols and CT scanners are given in the on-line
supplementary material (e-Table 1).
From 2007 onwards, most volumetric CTs were spirometer
controlled. Spirometer-controlled CT scanning was intro-
duced in our hospital to optimize inspiratory and expi-
ratory volume. If due to logistic reasons CT was not
spirometer controlled, then training for breath holds pri-
or to the scan and instructions during the scan were
given by the lung function technician (on-line supple-
mentary material).
Spirometry was performed at the annual evaluation using a
diagnostic system (Jaeger AG,Würzburg, Germany). The spi-
rometry parameters included for analysis were forced expira-
tory volume in 1 s (FEV1) and forced vital capacity (FVC).
FEV1 and FVC were expressed as a percentage of predictive
values, calculated using the Stanojevic et al. reference equa-
tions [16].
CTanalysis
According to the definition of the validated CF-CT scoring
system [17–19], bronchiectasis is present if the bronchial lu-
men diameter is larger than the adjacent pulmonary artery
outer diameter, or if there is a lack of tapering for at least
2 cm distal to a branching point. Based on literature about
the pathophysiology of bronchiectasis and based on the ex-
pertise of a panel consisting of a paediatric pulmonologist
(HT), a radiologist (PC), a biomedical imaging expert (MB)
and a PhD student (LT), five mutually exclusive categories for
classifying pre-stages of bronchiectasis were defined. These
categories were: (1) bronchiectasis (bronchial lumen diameter
is larger than the adjacent pulmonary artery outer diameter, or
lack of tapering for at least 2 cm, Fig. 1), (2) mucus plugging
(filling of clearly identifiable bronchi, Fig. 1), (3) airway wall
thickening (ratio between the bronchial wall thickness and the
outer diameter of the adjacent pulmonary artery being more
than 33 %, Fig. 1), (4) atelectasis or consolidation and (5)
normal airways. These categories are well defined as part of
the CF-CT scoring system and are further explained in the on-
line supplementary material [17–19].
CTs were de-identified and randomized. One observer (ob-
server 2: DZ) encircled all areas with bronchiectasis
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(bronchial lumen diameter-pulmonary artery outer diameter
ratio > 2 or saccular bronchiectasis) in the most recent volu-
metric inspiratory CT (CTbaseline). Those areas were marked as
a region of interest (ROI) using tools in our image analysis
platform (®Myrian Onco XL, Intrasense, France). By using
deformable image registration, the same areas were automat-
ically identified in the previous CTs (CTminus2-minus8). All pre-
ceding ROIs were assessed by two experienced observers with
respectively 1 and 2 years of experience (HO and DZ) and
assigned to one of the five above-mentioned categories.
Category 2–5 reflects a potential pre-stage in the ROI of the
bronchiectatic airway observed on the most recent CT.
ROIs were assessed in random order with respect to pa-
tients and order of CT scans (CTminus2-minus8). Therefore, the
observers had no knowledge of the assigned category of the
ROIs in previous or later scans.
Fig. 1 Illustration of scoring
categories: bronchiectasis (left),
mucus plugging (middle) and air-
way wall thickening (right)
Table 1 Baseline characteristics of the study cohort
Characteristic CTbaseline CTminus 2 CTminus 4 CTminus 6 CTminus 8
Number of patients 43 43 43 43 4
Number of regions of interest 367 367 367 367 46
Gender (males) 18 (41.9) 18 (41.9) 18 (41.9) 18 (41.9) 3 (75.0)
Age, year 15.3 (9–24) 13.2 (6–22) 11.0 (4–18) 9.0 (2–16) 6.8 (2–10)
SES#
Low 12 (29.3) 12 (29.3) 12 (29.3) 12 (29.3) 1 (25.0)
Average 15 (36.6) 15 (36.6) 15 (36.6) 15 (36.6) 1 (25.0)
High 13 (31.7) 13 (31.7) 13 (31.7) 13 (31.7) 2 (50.0)
Scientific 1 (2.4) 1 (2.4) 1 (2.4) 1 (2.4) 0 (0.0)
Genetics
Homozygous dF508 30 (69.8) 30 (69.8) 30 (69.8) 30 (69.8) 3 (75.0)
Heterozygous dF508 9 (20.9) 9 (20.9) 9 (20.9) 9 (20.9) 1 (25.0)
Heterozygous other mutation 4 (9.3) 4 (9.3) 4 (9.3) 4 (9.3) 0 (0.0)
Presence of co-morbidities‡
Pancreatic insufficient 40 (93.0) 40 (93.0) 40 (93.0) 40 (93.0) 3 (75.0)
CFRD 10 (23.3) 10 (23.3) 10 (23.3) 10 (23.3) 0 (0.0)
Asthma 3 (7.0) 3 (7.0) 3 (7.0) 3 (7.0) 0 (0.0)
ABPA 2 (4.7) 2 (4.7) 2 (4.7) 2 (4.7) 0 (0.0)
Chronic colonization Pa ‡‡ 8 (18.6) 8 (18.6) 8 (18.6) 8 (18.6) 1 (25.0)
BMI 19.2 (15–36) 18.0 (14–30) 17.0 (5–31) 16.5 (14–25) 15.7 (15–17)
FEV1, % predicted 86.5 (33–106) 85.4 (37–112) 85.0 (40–113) 85.8 (42–126) 88.4 (85–92)
FVC, % predicted 94.0 (49–115) 92.3 (56–128) 95.2 (57–118) 93.2 (49–128) 99.0 (94–102)
Data are presented as no. (%) or median (range)
CTbaseline–minus8 indicate the time points at which the CTs were made, with CTbaseline representing the most recent CT and CTminus2-8 respectively
representing the CT made 2, 4, 6 or 8 years before CTbaseline
# SES: socio-economic status based on the highest level of education of either parent (n = 41 at CTbaseline–minus6 and n = 4 at CTminus8)
‡ Indicating the number of patients having co-morbidities
‡ ‡ Chronic colonization Pa: defined as≥ three consecutive positive respiratory cultures for Pseudomonas aeruginosa (Pa) from birth to CTbaseline
CFRD CF-related diabetes, ABPA allergic bronchopulmonary aspergillosis, BMI body mass index, FEV1 forced expiratory volume in 1 s, FVC forced
vital capacity
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Statistical analysis
To assess observer agreement kappa scores were calculated.
For the interobserver agreement, a random subset of 35 pa-
tients with a total of 1,230 ROIs were scored by two observers
(H.O. and D.Z.). For the intra-observer agreement, a subset of
20 patients with 195 ROIs were rescored by H.O. after
1 month. In the final analyses, only the scores of observer
H.O. were used. Although no universally accepted standards
are available for what constitutes good agreement, kappa
scores of < 0.40, between 0.4 and 0.75, and ≥ 0.75 are con-
sidered to represent poor, moderate to good and excellent
agreement, respectively [20].
Descriptive statistics were used to describe the CT
findings.
We calculated how often bronchiectasis was persistent in
all CTs and how often it was directly preceded by mucus
plugging, airway wall thickening, atelectasis/consolidation,
or normal airways.
In order to distinguish patients who rapidly developed
bronchiectasis from previously normal airways from the ones
who were likely to have a pre-stage, we created two progres-
sion groups: a rapid progression group and a slow progression
group. The number of ROIs in which bronchiectasis was di-
rectly preceded by normal airways in any two successive
scans was calculated. The median number of these rapidly
progressing ROIs per patient was calculated (median = 3)
and used as the cut-off point to define the groups of rapid
and slow progressors. Patients who had more than three
ROIs in which normal airways became bronchiectatic within
2 years were thus included into the rapid progression group
(n = 21); the others were included in the slow progression
group (n=18). The two groups were compared with respect
to baseline characteristics using Chi-square tests.
SPSS version 13.0 was used for the analyses in this study.
Values are shown as median (range) unless otherwise indicat-
ed. P-values<0.05 (two-tailed) are considered to be statisti-
cally significant.
Results
Study population and CT data
Forty-three patients (18males)with amedian age of 15.3 years
(range 9–24 years) were included (Fig. 2). Of those 43 pa-
tients, 39 patients had four consecutive CTs and four patients
had five consecutive CTs. The median interval between two
CTs was 2.0 years (range 0.8–3.9). Baseline characteristics of
the study cohort are shown in Table 1.
In the CTbaseline of the included 43 patients, 367 unique
ROIs were identified. In 5/367 (1.4 %) ROIs, bronchiectasis
turned into a different category before being scored as
bronchiectasis in the baseline scan. In three of the five ROIs
the following pathway was identified: bronchiectasis in which
the CT immediately preceding the CT with bronchiectasis
showed normal airways, mucus plugging, bronchiectasis and
normal airways. In two of the five ROIs the following path-
way was identified: bronchiectasis in which the CT immedi-
ately preceding the CTwith bronchiectasis showed atelectasis/
consolidation, bronchiectasisand normal airways.
Previous literature showed that bronchiectasis is irrevers-
ible and therefore we excluded those 5/367 cases from further
analysis. An overview of the structural lung damage
(CTbaseline-CTminus8) in our study period is shown in Fig. 3.
The kappa for intra-observer agreement was 0.77 and for
interobserver agreement 0.48. More detailed information
about the intra- and interobserver agreement is displayed in
Table 1 in the on-line supplementary material.
Bronchiectasis and pre-stages (Fig. 3)
In 187 of the 362 (51.7 %) ROIs bronchiectasis was persistent
in all available CTs. For the remaining 175 ROIs in which
development of bronchiectasis could be observed, the CT im-
mediately preceding the first CT with bronchiectasis showed
Fig. 2 Flowchart of the study population. CF cystic fibrosis, ROIs
regions of interest
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normal airways (139/175, 79.4 %), mucus plugging (31/175,
17.7 %), airway wall thickening (3/175, 1.7 %) or atelectasis/
consolidation (2/175, 1.1 %).
The most commonly identified pre-stage of bronchiectasis
was mucus plugging. In 23 ROIs mucus plugging turned into
bronchiectasis within one CT (2 years, range 1.7–2.4). In the
other eight ROIs mucus plugging persisted for two CTs
(4 years, range 3.7–5.9) before progression to bronchiectasis.
Mucus plugging never remained longer than three consecutive
CTs, without progressing to bronchiectasis.
Progression to bronchiectasis
Based on the median number of three ROIs per patient that
progressed from normal to bronchiectasis in 2 years, we in-
cluded 21 patients in the rapid progression group and 18 pa-
tients in the slow progression group. There was no statistical
difference between these groups with regard to gender
(p = 0.47), socioeconomic status (p = 0.49), genetic defect
(p = 0.78), CF-related diabetes (CFRD, p = 0.16), asthma
(p=0.12), allergic bronchopulmonary aspergillosis (ABPA,
p = 0.12) or chronic Pseudomonas aeruginosa infection
(p = 0.39). However, there was a borderline significant
difference (p=0.05) for pancreatic insufficiency: all patients
included in the rapid group were pancreatic insufficient, while
15 of the 18 patients in the slow progression group were pan-
creatic insufficient.
Discussion
This is the first longitudinal study of CT-diagnosed bronchi-
ectasis aiming to identify CT detectable pre-stages of bronchi-
ectasis in children with CF. We assessed the evolution of
uniquely identified ROIs using a deformable image registra-
tion technique. Our observations provide a unique insight into
the radiological course of developing bronchiectasis.
Our most important findings are that most bronchiectasis
appeared within the 2-year timeframe between successive
scans. Of the pre-stages that could be identified, mucus plug-
ging was the most common predecessor of bronchiectasis.
Mucus plugging was identified as a potential pre-stage of
bronchiectasis. Although no previous studies focused on iden-
tifying pre-stages of bronchiectasis have been performed, an
earlier study from our group identified mucus plugging as an
indicator for bronchiectasis 6 years later [21]. Those results
Fig. 3 Structural lung damage over time (n = 362 in 43 patients). Dark
grey represents bronchiectasis, light-dark grey (area above dark grey)
represents mucus plugging, grey dots represent airway wall thickening,
white dots represent atelectasis/consolidation, light grey (on top) repre-
sents normal airways. CTbaseline is the most recent CT
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suggest a transition from mucus plugging to bronchiectasis,
implying that optimising mucociliary clearance treatment is
important to prevent bronchiectasis in CF. However, this hy-
pothesis requires further investigation in a prospective CT
study.
Development of bronchiectasis without clearly identifiable
pre-stages 2 years earlier was commonly seen in this study. It
is possible that the development of most bronchiectasis is an
acute process and not caused by a slow continuous progres-
sive transition. Therefore, we hypothesized that there are two
possible phenotypes: one for rapid progression of bronchiec-
tasis and one for more slowly developing bronchiectasis.
A sub-group analysis (rapid vs. slow progression) was per-
formed to identify risk factors for the acute development of
bronchiectasis in our relatively small single-centre cohort.
This sub-group analysis showed only a borderline significant
difference in baseline characteristics between the pancreatic
status in the two groups. All patients in the rapid progression
group were pancreatic insufficient, versus 80 % of the patients
in the slow progression group. The importance of pancreatic
status as a marker of disease severity has been observed in
other studies [6, 22]. Although we could not identify an asso-
ciation between severe CFTR genotype and progression of
bronchiectasis in our cohort aged 9–24 years, we must ac-
knowledge our small sample size, which may have resulted
in inadequate power to detect this association. Previous re-
search by Mott et al. [6] did observe a significant association
between genotype and bronchiectasis progression in children
below the age of 6 years.
To gain further insight into the pathophysiology of bron-
chiectasis, it would be interesting to also include trapped air in
the analyses, given that an association between trapped air and
persistence or progression of bronchiectasis has recently been
shown in young children with CF [6]. The most sensitive
method to detect trapped air is an expiratory spirometer-
controlled CT [23]. For our current study, we did not have
sufficient spirometer-controlled expiratory CTs to include this
analysis.
There are some limitations to this study. The longitudi-
nal, retrospectively analysed data used in this study were
collected from a single centre, which may reduce the gen-
eralizability of our results. Data were collected as part of
the annual evaluation. During the study period our annual
evaluation protocol changed to improve the structure of the
follow-up schedule for routine chest CTs so that every
child has a CT at the same age (2, 4, 6, 8, 10, 12, 14, 16
and 18 years) resulting in a larger time range between two
CTs for some patients. CTs were performed on different
CT scanners, due to the introduction of newer and quicker
CT scanners. Furthermore, CT protocols changed during
our study period to low-dose CT protocols and
spirometer-controlled CT scanning, to reduce radiation
and improve image quality [23]. We cannot exclude that
the use of these different CT scanners and CT protocols
may have reduced the sensitivity to detect pre stages of
bronchiectasis. However, it is well recognized that the
use of scoring systems is relatively insensitive to differ-
ences in CT scanners and CT protocols [24]. Our study is
the first to identify ROIs and retrospectively assess the
status of these regions in the years preceding bronchiecta-
sis; this scoring strategy has not been used in other studies.
Nevertheless, the kappa scores for the intra- and interob-
server variability for the sub-scores were above 0.77 and
0.48, respectively. This suggests that our approach was
sufficiently reproducible. Regarding the 301 ROIs with
bronchiectasis in CTbaseline, the two observers scored the
same in all but four ROIs, indicating an excellent agree-
ment between observers regarding baseline bronchiectasis.
A disadvantage of our scoring method is that we may have
missed changes such as subtle airway wall thickening, as
scoring is considered a not very sensitive and reproducible
method to quantify airway wall thickening [19]; in most
CT-scoring studies the kappa for airway wall thickening is
low. It is also very possible that when more sensitive au-
tomated image analysis tools are developed, subtle changes
can be picked up and more pre-stages can be identified.
Clinical implications
Our study shows the treacherous nature of CF lung disease
in a cohort of patients who are receiving standard treatment
as in the majority of cases bronchiectasis developed within
2 years without identifiable pre-stages. The only pre-stage
that was identified in 17.7 % of cases of bronchiectasis was
mucous impaction. Hence, this observation in a patient
warrants close attention by the CF team to further improve
mucociliary clearance. Furthermore, our results suggest
that in some patients the development of bronchiectasis
can occur rapidly. The identification of pre-stages of bron-
chiectasis early on might create a treatment opportunity
before irreversible bronchiectasis occurs. Therefore, an an-
nual CT may be considered in children with a rapid pro-
gression of bronchiectasis. Nevertheless, additional studies
are needed to identify the risk factors leading to the sudden
development of bronchiectasis. In future clinical interven-
tion studies are needed that aim to prevent this ‘sudden’
development of bronchiectasis.
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